RayzeBio, Inc. (RYZB)
| Market Cap | 1.14B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.31M |
| Shares Out | 58.20M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,805 |
| Open | 19.78 |
| Previous Close | 19.78 |
| Day's Range | 19.52 - 20.92 |
| 52-Week Range | 18.00 - 26.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2023 |
About RYZB
RayzeBio is building a vertically integrated radiopharmaceutical therapeutics company with our lead program in a Phase 3 clinical trial. We have created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Our lead drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225, or Ac225, to tumors overexpressing SSTR2. We are enrolling in a registrational Phase 3 clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors, or ... [Read more]
Financial Performance
Financial StatementsNews
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the closing o...
RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion
Investors cheered RayBio Inc. as it debuted on Wall Street, as the California-based radiopharmaceutical company's stock RYZB, +39.13% opened 38.9% above the initial public offering price. The company ...
RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RayzeBio Inc. RYZB, has secured a near-$1 billion market valuation, as the California-based radiopharmaceutical company's upsized initial public offering priced at the top end of the expected range. T...
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing o...
RayzeBio sets IPO terms, to be valued at up to $1 billion
RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a Phase 3 trial looks to raise up to about $238.2 milli...
RayzeBio Appoints Christy Oliger to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of dir...
RayzeBio IPO Registration Document (S-1)
RayzeBio has filed to go public with an IPO on the NASDAQ.